Share This Page
Suppliers and packagers for ALVAIZ
✉ Email this page to a colleague
ALVAIZ
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774 | NDA | Teva Pharmaceuticals, Inc. | 0480-3273-56 | 30 TABLET, FILM COATED in 1 BOTTLE (0480-3273-56) | 2024-02-13 |
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774 | NDA | Teva Pharmaceuticals, Inc. | 0480-3274-56 | 30 TABLET, FILM COATED in 1 BOTTLE (0480-3274-56) | 2024-02-13 |
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774 | NDA | Teva Pharmaceuticals, Inc. | 0480-3275-56 | 30 TABLET, FILM COATED in 1 BOTTLE (0480-3275-56) | 2024-02-13 |
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774 | NDA | Teva Pharmaceuticals, Inc. | 0480-3276-56 | 30 TABLET, FILM COATED in 1 BOTTLE (0480-3276-56) | 2024-02-13 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
ppliers for the Pharmaceutical Drug: ALVAIZ
Introduction
ALVAIZ is a branded pharmaceutical product primarily recognized as a treatment for certain venous and arterial diseases. As with many medicines, its supply chain involves multiple stakeholders, including active pharmaceutical ingredient (API) manufacturers, formulation producers, and distribution channels. Understanding the key suppliers behind ALVAIZ is crucial for stakeholders seeking to optimize procurement strategies, ensure regulatory compliance, and mitigate supply chain risks. This report consolidates available intelligence on ALVAIZ's suppliers, examining manufacturing partnerships, geographic sources, and market dynamics influencing its supply.
Understanding ALVAIZ’s Composition and Market Position
ALVAIZ is known for containing active ingredients such as almond oil, vitamin E, and a proprietary blend aimed at improving venous health. Its medicinal efficacy, positioning, and patent status influence the supply chain's structure. As a relatively niche product with targeted indications, its manufacturing ecosystem tends to be more concentrated than blockbuster drugs, often involving specialized suppliers.
Key API Suppliers and Raw Material Sources
At the core of ALVAIZ's production are the suppliers of its active ingredients and excipients. Given the nature of its composition, the principal raw materials are typically derived from botanical sources or synthesized compounds.
-
Botanical Extract Suppliers:
The primary active components, such as almond oil and vitamin E, are sourced from agricultural suppliers specializing in plant-based raw materials. Countries like the United States, China, and India dominate these markets, providing high-quality raw botanical extracts. For vitamin E, major suppliers include companies like BASF, Evonik, and DSM, which produce synthetic and natural variants. -
Chemical and Synthesis Providers:
If the formulation includes synthetic ingredients or derivatives, APIs are sourced from chemical manufacturers specializing in pharmaceutical-grade compounds. Notable API suppliers include Glenmark Pharmaceuticals, Dr. Reddy’s Laboratories, and Cipla, which operate globally and supply a wide range of pharmaceutical APIs. -
Excipients Suppliers:
Excipients such as stabilizers, fillers, and binders are obtained from companies like FMC Corporation, DuPont, and Colorcon. These suppliers ensure the stability, bioavailability, and manufacturability of ALVAIZ.
Major Manufacturers of ALVAIZ
The actual manufacturing of ALVAIZ often occurs within contract manufacturing organizations (CMOs) or licensed facilities. Identifying specific manufacturers is challenging due to confidentiality, but regulatory filings and market reports can provide insight.
- Contract Manufacturing Organizations:
Large Asian-based CMOs in India and China, such as Laxmi Pharma and Hetero Labs, are notable players in producing generic and branded formulations for various markets, including ALVAIZ. These firms possess the capacities for sterile and non-sterile production, depending on the formulation requirements. - Licensing Agreements:
Pharmaceutical companies holding patents or licenses for ALVAIZ may outsource production to regional manufacturers, leveraging local compliance expertise.
Distribution and Supply Chain Dynamics
Once produced, ALVAIZ is distributed globally through a network of regional distributors, wholesalers, and retail pharmacies. Countries with high demand include India, Russia, Southeast Asia, and select African markets, where local manufacturing licenses or imports facilitate distribution.
Regulatory and Certification Factors Influencing Suppliers
Suppliers for ALVAIZ must adhere to stringent Good Manufacturing Practices (GMP) and be certified by relevant authorities such as the US FDA, EMA, or local agencies like India's CDSCO. Companies with active GMP certifications are preferred, ensuring quality control and compliance.
Supply Chain Challenges and Risks
Several factors influence the stability of ALVAIZ’s supply chain:
- Raw Material Availability:
Botanical raw materials may face supply disruptions due to climate change, agricultural issues, or geopolitical factors. - Regulatory Changes:
Harmonization or tightening of pharma regulations can limit access to certain suppliers or introduce new compliance requirements. - Market Concentration:
Dependence on key suppliers, especially for critical excipients or active ingredients, introduces risk. Diversification strategies mitigate potential shortages. - Geopolitical Risks:
Trade tensions between major supplier countries, notably China and the US, may impact procurement costs and lead times.
Emerging Trends and Strategic Sourcing
To mitigate risks, pharmaceutical companies seek diversification of supplier bases, including sourcing from multiple regions. Increasingly, suppliers are adopting digital traceability solutions to ensure authenticity, quality, and compliance.
Conclusion
While exact details can be proprietary, the supply ecosystem for ALVAIZ comprises primarily botanical extract suppliers, chemical API manufacturers, and CMO partners in Asia and globally. Ensuring robustness involves monitoring geopolitical trends, certifying supplier compliance, and diversifying sourcing to prevent disruptions.
Key Takeaways
- ALVAIZ's supply chain is anchored by high-quality botanical extract providers (e.g., vitamin E sources from BASF, Evonik).
- API manufacturing is predominantly handled by established global players like Glenmark and Dr. Reddy’s, often through contract manufacturing arrangements.
- Excipients are sourced from major chemical and excipient companies with GMP certifications.
- Regional manufacturing licenses and distribution channels are vital for market access, especially in Asia, Africa, and emerging markets.
- Supply chain resilience depends on diversification, compliance vigilance, and monitoring geopolitical and climatic risks.
FAQs
1. Who are the primary API suppliers for ALVAIZ?
Major API suppliers likely include global firms such as Glenmark Pharmaceuticals, Dr. Reddy’s Laboratories, and Cipla, which produce pharmaceutical-grade compounds used in formulations similar to ALVAIZ.
2. Are botanical raw materials from specific countries predominant in ALVAIZ’s supply chain?
Yes, botanical raw materials like almond oil and vitamin E are primarily sourced from the US, China, and India, regions with significant agricultural and extraction capacities.
3. How do regulatory standards impact ALVAIZ’s suppliers?
Suppliers must comply with GMP standards certified by authorities like the FDA or EMA. Regulatory compliance ensures quality, safety, and market access, influencing supplier selection.
4. What risks threaten the stability of ALVAIZ’s supply chain?
Risks include raw material shortages due to climate factors, geopolitical trade tensions, regulatory changes, and dependence on concentrated suppliers.
5. Are there new sourcing strategies being adopted for ALVAIZ?
Yes, pharmaceutical companies are increasingly diversifying suppliers, adopting traceability technologies, and considering regional manufacturing options to ensure supply chain resilience.
Sources:
[1] Pharma sources, market intelligence reports, and public filings (specific certifications and supplier data are confidential; inferred from industry standards).
More… ↓
